Drugs in development · updated 9 November 2026
Milrinone: clinical trials and development status
Other names and codes: Primacor
As of 9 November 2026 Milrinone is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 3 diseases. The most advanced phase is III.
Summary updated every week · data as of 9 November 2026. In Phuturdex you can follow Milrinone and get an email at every change or safety alert.
Sign in free →What it is
A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Heart failure | II | 1 | NCT05450328 |
| Right ventricular dysfunction | II | 1 | NCT05450328 |
| Subarachnoid hemorrhage | II | 1 | NCT04282629 |
Everything on Milrinone
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 9 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.